The Mechanisms of HBV-Induced Hepatocellular Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Suppl 4):5–13. doi:10.1634/theoncologist.2010-S4-05
   PubMed Web of Science ®Google Scholar
• Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155(4):323–331. doi:10.1093/aje/155.4.323
   PubMed Web of Science ®Google Scholar
• Wild CP, Montesano R. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett. 2009;286(1):22–28. doi:10.1016/j.canlet.2009.02.053
   Web of Science ®Google Scholar
• Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Semin Liver Dis. 2013;33(2):97–102. doi:10.1055/s-0033-1345716
   PubMed Web of Science ®Google Scholar
• Wei F, Zheng Q, Li M, Wu M. The association between hepatitis B mutants and hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore). 2017;96(19):e6835. doi:10.1097/MD.0000000000006835
   PubMed Web of Science ®Google Scholar
• Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol. 2014;61(2):408–417. doi:10.1016/j.jhep.2014.04.041
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu Y, Deng M, et al. CD8(+) T-cell response-associated evolution of hepatitis B virus core protein and disease progress. J Virol. 2018;92(17). doi:10.1128/JVI.02120-17.
   Web of Science ®Google Scholar
• Wu JF, Ni YH, Chen HL, Hsu HY, Chang MH. The impact of hepatitis B virus precore/core gene carboxyl terminal mutations on viral biosynthesis and the host immune response. J Infect Dis. 2014;209(9):1374–1381. doi:10.1093/infdis/jit638
   Web of Science ®Google Scholar
• Sun L, Zhang Y, Zhao B, et al. A new unconventional HLA-A2-restricted epitope from HBV core protein elicits antiviral cytotoxic T lymphocytes. Protein Cell. 2014;5(4):317–327. doi:10.1007/s13238-014-0041-4
   Web of Science ®Google Scholar
• Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell. 2019;179(2):561–577 e522. doi:10.1016/j.cell.2019.08.052
   PubMed Web of Science ®Google Scholar
• Liu Y, Tao S, Liao L, et al. TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway. Nat Commun. 2020;11(1):348. doi:10.1038/s41467-019-14190-2
   PubMed Web of Science ®Google Scholar
• Trung NT, Hoan NX, Trung PQ, et al. Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma. Sci Rep. 2020;10(1):8181. doi:10.1038/s41598-020-65213-8
   Web of Science ®Google Scholar
• Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014;46(12):1267–1273. doi:10.1038/ng.3126
   PubMed Web of Science ®Google Scholar
• Hu C, Li W, Tian F, et al. Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma. J Hepatol. 2018;68(3):465–475. doi:10.1016/j.jhep.2017.10.028
   PubMed Web of Science ®Google Scholar
• Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63(1):173–184. doi:10.1002/hep.28251
   PubMed Web of Science ®Google Scholar
• Yuan X, Larsson C, Xu D. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene. 2019;38(34):6172–6183. doi:10.1038/s41388-019-0872-9
   PubMed Web of Science ®Google Scholar
• Xie Y. Hepatitis B virus-associated hepatocellular carcinoma. Adv Exp Med Biol. 2017;1018:11–21.
   PubMed Web of Science ®Google Scholar
• Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol. 2000;10(3):211–231. doi:10.1006/scbi.2000.0321
   PubMed Web of Science ®Google Scholar
• Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44(7):765–769. doi:10.1038/ng.2295
   PubMed Web of Science ®Google Scholar
• Fujimoto A, Totoki Y, Abe T, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012;44(7):760–764. doi:10.1038/ng.2291
   PubMed Web of Science ®Google Scholar
• Matsubara K, Tokino T. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med. 1990;7(3):243–260.
   Google Scholar
• Lee WY, Bachtiar M, Choo CCS, Lee CG. Comprehensive review of Hepatitis B virus-associated hepatocellular carcinoma research through text mining and big data analytics. Biol Rev Camb Philos Soc. 2019;94(2):353–367. doi:10.1111/brv.12457
   Web of Science ®Google Scholar
• Zhang Y, Yan Q, Gong L, et al. C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism. Oncogene. 2020.
   Web of Science ®Google Scholar
• Mao X, Tey SK, Ko FCF, et al. C-terminal truncated HBx protein activates caveolin-1/LRP6/beta-catenin/FRMD5 axis in promoting hepatocarcinogenesis. Cancer Lett. 2019;444:60–69. doi:10.1016/j.canlet.2018.12.003
   PubMed Web of Science ®Google Scholar
• Li W, Li M, Liao D, et al. Carboxyl-terminal truncated HBx contributes to invasion and metastasis via deregulating metastasis suppressors in hepatocellular carcinoma. Oncotarget. 2016;7(34):55110–55127. doi:10.18632/oncotarget.10399
   Google Scholar
• Sze KM, Chu GK, Lee JM, Ng IO. C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma. Hepatology. 2013;57(1):131–139. doi:10.1002/hep.25979
   PubMed Web of Science ®Google Scholar
• Choi YM, Lee SY, Kim BJ. Naturally occurring Hepatitis B virus mutations leading to endoplasmic reticulum stress and their contribution to the progression of hepatocellular carcinoma. Int J Mol Sci. 2019;20(3). doi:10.3390/ijms20030597
   Web of Science ®Google Scholar
• Montalbano R, Honrath B, Wissniowski TT, et al. Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells. Oncotarget. 2016;7(15):20312–20323. doi:10.18632/oncotarget.7950
   Google Scholar
• Li X, Zhang J, Yang Z, et al. The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma. J Hepatol. 2014;60(5):975–984. doi:10.1016/j.jhep.2013.12.014
   PubMed Web of Science ®Google Scholar
• Zhao LH, Liu X, Yan HX, et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat Commun. 2016;7:12992. doi:10.1038/ncomms12992
   PubMed Web of Science ®Google Scholar
• Li W, Zeng X, Lee NP, et al. HIVID: an efficient method to detect HBV integration using low coverage sequencing. Genomics. 2013;102(4):338–344. doi:10.1016/j.ygeno.2013.07.002
   PubMed Web of Science ®Google Scholar
• Yang L, Ye S, Zhao X, et al. Molecular characterization of HBV DNA integration in patients with hepatitis and hepatocellular carcinoma. J Cancer. 2018;9(18):3225–3235. doi:10.7150/jca.26052
   Web of Science ®Google Scholar
• D’Souza S, Lau KC, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol. 2020;26(38):5759–5783. doi:10.3748/wjg.v26.i38.5759
   PubMed Web of Science ®Google Scholar
• Toh ST, Jin Y, Liu L, et al. Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations. Carcinogenesis. 2013;34(4):787–798. doi:10.1093/carcin/bgs406
   PubMed Web of Science ®Google Scholar
• Nault JC, Ningarhari M, Rebouissou S, Zucman-Rossi J. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol. 2019;16(9):544–558. doi:10.1038/s41575-019-0165-3
   PubMed Web of Science ®Google Scholar
• Sze KM, Ho DW, Chiu YT, et al. Hepatitis B virus-telomerase reverse transcriptase promoter integration harnesses host ELF4, resulting in telomerase reverse transcriptase gene transcription in hepatocellular carcinoma. Hepatology. 2020;73:23–40. doi:10.1002/hep.31231
   Web of Science ®Google Scholar
• Saitta C, Tripodi G, Barbera A, et al. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Liver Int. 2015;35(10):2311–2317. doi:10.1111/liv.12807
   Web of Science ®Google Scholar
• Wong DK, Cheng SCY, Mak LL, et al. Among patients with undetectable Hepatitis B surface antigen and hepatocellular carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis. Clin Gastroenterol Hepatol. 2020;18(2):449–456. doi:10.1016/j.cgh.2019.06.029
   PubMed Web of Science ®Google Scholar
• Matsuzaki Y, Chiba T, Hadama T, et al. HBV genome integration and genetic instability in HBsAg-negative and anti-HCV-positive hepatocellular carcinoma in Japan. Cancer Lett. 1997;119(1):53–61. doi:10.1016/S0304-3835(97)00249-8
   Web of Science ®Google Scholar
• Mak LY, Wong DK, Pollicino T, Raimondo G, Hollinger FB, Yuen MF. Occult hepatitis B infection and hepatocellular carcinoma: epidemiology, virology, hepatocarcinogenesis and clinical significance. J Hepatol. 2020;73(4):952–964. doi:10.1016/j.jhep.2020.05.042
   PubMed Web of Science ®Google Scholar
• Chen L, Ming X, Li W, et al. The microRNA-155 mediates hepatitis B virus replication by reinforcing SOCS1 signalling-induced autophagy. Cell Biochem Funct. 2020;38(4):436–442. doi:10.1002/cbf.3488
   Web of Science ®Google Scholar
• Dai X, Zhang W, Zhang H, et al. Modulation of HBV replication by microRNA-15b through targeting hepatocyte nuclear factor 1alpha. Nucleic Acids Res. 2014;42(10):6578–6590. doi:10.1093/nar/gku260
   PubMed Web of Science ®Google Scholar
• Jin J, Tang S, Xia L, et al. MicroRNA-501 promotes HBV replication by targeting HBXIP. Biochem Biophys Res Commun. 2013;430(4):1228–1233. doi:10.1016/j.bbrc.2012.12.071
   Web of Science ®Google Scholar
• Wang Y, Li Y. miR-146 promotes HBV replication and expression by targeting ZEB2. Biomed Pharmacother. 2018;99:576–582. doi:10.1016/j.biopha.2018.01.097
   Web of Science ®Google Scholar
• Hou Z, Zhang J, Han Q, et al. Hepatitis B virus inhibits intrinsic RIG-I and RIG-G immune signaling via inducing miR146a. Sci Rep. 2016;6:26150. doi:10.1038/srep26150
   PubMed Web of Science ®Google Scholar
• Hou ZH, Han QJ, Zhang C, Tian ZG, Zhang J. miR146a impairs the IFN-induced anti-HBV immune response by downregulating STAT1 in hepatocytes. Liver Int. 2014;34(1):58–68. doi:10.1111/liv.12244
   Web of Science ®Google Scholar
• Wang G, Dong F, Xu Z, et al. MicroRNA profile in HBV-induced infection and hepatocellular carcinoma. BMC Cancer. 2017;17(1):805. doi:10.1186/s12885-017-3816-1
   PubMed Web of Science ®Google Scholar
• Morishita A, Fujita K, Iwama H, et al. Role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol. 2020;318(3):G401–G409. doi:10.1152/ajpgi.00269.2019
   Web of Science ®Google Scholar
• Zhu HT, Liu RB, Liang YY, et al. Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma. Liver Int. 2017;37(6):888–896. doi:10.1111/liv.13356
   PubMed Web of Science ®Google Scholar
• Chen S, Chen H, Gao S, et al. Differential expression of plasma microRNA-125b in hepatitis B virus-related liver diseases and diagnostic potential for hepatitis B virus-induced hepatocellular carcinoma. Hepatol Res. 2017;47(4):312–320. doi:10.1111/hepr.12739
   PubMed Web of Science ®Google Scholar
• Li R, Xu T, Wang H, et al. Dysregulation of the miR-325-3p/DPAGT1 axis supports HBV-positive HCC chemoresistance. Biochem Biophys Res Commun. 2019;519(2):358–365. doi:10.1016/j.bbrc.2019.08.116
   PubMed Web of Science ®Google Scholar
• Sadri Nahand J, Bokharaei-Salim F, Salmaninejad A, et al. microRNAs: key players in virus-associated hepatocellular carcinoma. J Cell Physiol. 2019;234(8):12188–12225. doi:10.1002/jcp.27956
   Web of Science ®Google Scholar
• Tian JH, Liu WD, Zhang ZY, et al. Influence of miR-520e-mediated MAPK signaling pathway on HBV replication and regulation of hepatocellular carcinoma cells via targeting EphA2. J Viral Hepat. 2018.
   Web of Science ®Google Scholar
• Lou W, Liu J, Ding B, et al. Identification of potential miRNA-mRNA regulatory network contributing to pathogenesis of HBV-related HCC. J Transl Med. 2019;17(1):7. doi:10.1186/s12967-018-1761-7
   PubMed Web of Science ®Google Scholar
• Kong XX, Lv YR, Shao LP, et al. HBx-induced MiR-1269b in NF-kappaB dependent manner upregulates cell division cycle 40 homolog (CDC40) to promote proliferation and migration in hepatoma cells. J Transl Med. 2016;14(1):189. doi:10.1186/s12967-016-0949-y
   PubMed Web of Science ®Google Scholar
• Wang J, Chen J, Liu Y, et al. Hepatitis B virus induces autophagy to promote its replication by the axis of miR-192-3p-XIAP through NF kappa B signaling. Hepatology. 2019;69(3):974–992. doi:10.1002/hep.30248
   PubMed Web of Science ®Google Scholar
• Yao L, Zhou Y, Sui Z, et al. HBV-encoded miR-2 functions as an oncogene by downregulating TRIM35 but upregulating RAN in liver cancer cells. EBioMedicine. 2019;48:117–129. doi:10.1016/j.ebiom.2019.09.012
   PubMed Web of Science ®Google Scholar
• Zhao X, Sun L, Mu T, et al. An HBV-encoded miRNA activates innate immunity to restrict HBV replication. J Mol Cell Biol. 2020;12(4):263–276. doi:10.1093/jmcb/mjz104
   Web of Science ®Google Scholar
• Chavalit T, Nimsamer P, Sirivassanametha K, et al. Hepatitis B virus-encoded microRNA (HBV-miR-3) regulates host gene PPM1A related to hepatocellular carcinoma. Microrna. 2020;9(3):232–239. doi:10.2174/2211536608666191104105334
   PubMedGoogle Scholar
• Liang HW, Wang N, Wang Y, et al. Hepatitis B virus-human chimeric transcript HBx-LINE1 promotes hepatic injury via sequestering cellular microRNA-122. J Hepatol. 2016;64(2):278–291. doi:10.1016/j.jhep.2015.09.013
   Web of Science ®Google Scholar
• Sartorius B, Makarova J, Sartorius B, et al. The regulatory role of microRNA in Hepatitis-B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) pathogenesis. Cells. 2019;8(12):1504. doi:10.3390/cells8121504
   Web of Science ®Google Scholar
• Sun W, Zhang J, Chen J. MicroRNA-520a suppresses HBV replication in HepG2.2.15 cells by inactivating AKT. J Int Med Res. 2018;46(11):4693–4704. doi:10.1177/0300060518792780
   Web of Science ®Google Scholar
• Hamada-Tsutsumi S, Naito Y, Sato S, et al. The antiviral effects of human microRNA miR-302c-3p against hepatitis B virus infection. Aliment Pharmacol Ther. 2019;49(8):1060–1070. doi:10.1111/apt.15197
   Web of Science ®Google Scholar
• Mao K, Zhang J, He C, et al. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Cancer Lett. 2014;352(2):245–252. doi:10.1016/j.canlet.2014.07.004
   PubMed Web of Science ®Google Scholar
• Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. 2017;357:6348. doi:10.1126/science.aal2380
   Web of Science ®Google Scholar
• Song MA, Kwee SA, Tiirikainen M, et al. Comparison of genome-scale DNA methylation profiles in hepatocellular carcinoma by viral status. Epigenetics. 2016;11(6):464–474. doi:10.1080/15592294.2016.1151586
   PubMed Web of Science ®Google Scholar
• Park IY, Sohn BH, Yu E, et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology. 2007;132(4):1476–1494. doi:10.1053/j.gastro.2007.01.034
   PubMed Web of Science ®Google Scholar
• Zhao J, Wu G, Bu F, et al. Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology. 2010;51(1):142–153. doi:10.1002/hep.23247
   Web of Science ®Google Scholar
• Gao W, Jia Z, Tian Y, et al. HBx protein contributes to liver carcinogenesis by H3K4me3 modification through stabilizing WD repeat domain 5 protein. Hepatology. 2020;71(5):1678–1695. doi:10.1002/hep.30947
   Web of Science ®Google Scholar
• Yoo YG, Na TY, Seo HW, et al. Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene. 2008;27(24):3405–3413. doi:10.1038/sj.onc.1211000
   PubMed Web of Science ®Google Scholar
• Salerno D, Chiodo L, Alfano V, et al. Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription. Gut. 2020;69(11):2016–2024. doi:10.1136/gutjnl-2019-319637
   PubMed Web of Science ®Google Scholar
• Aicher S, Kakkanas A, Cohen L, et al. Differential regulation of the Wnt/beta-catenin pathway by hepatitis C virus recombinants expressing core from various genotypes. Sci Rep. 2018;8(1):11185. doi:10.1038/s41598-018-29078-2
   Web of Science ®Google Scholar
• Daud M, Rana MA, Husnain T, Ijaz B. Modulation of Wnt signaling pathway by hepatitis B virus. Arch Virol. 2017;162(10):2937–2947. doi:10.1007/s00705-017-3462-6
   Web of Science ®Google Scholar
• Liu Y, Ye X, Zhang JB, et al. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing beta-catenin expression and nuclear translocation. Oncogene. 2015;34(44):5524–5535. doi:10.1038/onc.2015.7
   PubMed Web of Science ®Google Scholar
• Huang M, Chen C, Geng J, et al. Targeting KDM1A attenuates Wnt/beta-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett. 2017;398:12–21. doi:10.1016/j.canlet.2017.03.038
   PubMed Web of Science ®Google Scholar
• Lin X, Li AM, Li YH, et al. Silencing MYH9 blocks HBx-induced GSK3beta ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):13. doi:10.1038/s41392-020-0111-4
   PubMed Web of Science ®Google Scholar
• Hsieh A, Kim HS, Lim SO, Yu DY, Jung G. Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/beta-catenin signaling. Cancer Lett. 2011;300(2):162–172. doi:10.1016/j.canlet.2010.09.018
   Web of Science ®Google Scholar
• Monga SP. Beta-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology. 2015;148(7):1294–1310. doi:10.1053/j.gastro.2015.02.056
   PubMed Web of Science ®Google Scholar
• Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627–644. doi:10.1038/nrd2926
   PubMed Web of Science ®Google Scholar
• Chung TW, Lee YC, Ko JH, Kim CH. Hepatitis B virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res. 2003;63(13):3453–3458.
   Web of Science ®Google Scholar
• Ha HL, Yu DY. HBx-induced reactive oxygen species activates hepatocellular carcinogenesis via dysregulation of PTEN/Akt pathway. World J Gastroenterol. 2010;16(39):4932–4937. doi:10.3748/wjg.v16.i39.4932
   Web of Science ®Google Scholar
• Kim GW, Imam H, Khan M, et al. HBV-induced increased N6 methyladenosine modification of PTEN RNA affects innate immunity and contributes to HCC. Hepatology. 2020;73:533–547. doi:10.1002/hep.31313
   Web of Science ®Google Scholar
• Khattar E, Mukherji A, Kumar V. Akt augments the oncogenic potential of the HBx protein of hepatitis B virus by phosphorylation. FEBS J. 2012;279(7):1220–1230. doi:10.1111/j.1742-4658.2012.08514.x
   PubMed Web of Science ®Google Scholar
• Chiu AP, Tschida BR, Sham TT, et al. HBx-K130M/V131I promotes liver cancer in transgenic mice via AKT/FOXO1 signaling pathway and arachidonic acid metabolism. Mol Cancer Res. 2019;17(7):1582–1593. doi:10.1158/1541-7786.MCR-18-1127
   Web of Science ®Google Scholar
• Chang WW, Su IJ, Chang WT, Huang W, Lei HY, Lei H-Y. Suppression of p38 mitogen-activated protein kinase inhibits hepatitis B virus replication in human hepatoma cell: the antiviral role of nitric oxide. J Viral Hepat. 2008;15(7):490–497. doi:10.1111/j.1365-2893.2007.00968.x
   Web of Science ®Google Scholar
• Kim SY, Kim H, Kim SW, et al. An effective antiviral approach targeting Hepatitis B virus with NJK14047, a novel and selective biphenyl amide p38 mitogen-activated protein kinase inhibitor. Antimicrob Agents Chemother. 2017;61(8). doi:10.1128/AAC.00214-17.
   Web of Science ®Google Scholar
• Witt-Kehati D, Fridkin A, Alaluf MB, Zemel R, Shlomai A. Inhibition of pMAPK14 overcomes resistance to sorafenib in hepatoma cells with Hepatitis B virus. Transl Oncol. 2018;11(2):511–517. doi:10.1016/j.tranon.2018.02.015
   Web of Science ®Google Scholar
• Liao B, Zhou H, Liang H, Li C. Regulation of ERK and AKT pathways by hepatitis B virus X protein via the Notch1 pathway in hepatocellular carcinoma. Int J Oncol. 2017;51(5):1449–1459. doi:10.3892/ijo.2017.4126
   Web of Science ®Google Scholar
• Li M, Zhou ZH, Sun XH, et al. Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway: a possible mechanism of hepatitis B virus persistence. Lab Invest. 2016;96(11):1156–1164. doi:10.1038/labinvest.2016.96
   Web of Science ®Google Scholar
• Valgimigli M, Valgimigli L, Trere D, et al. Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation. Free Radic Res. 2002;36(9):939–948. doi:10.1080/107156021000006653
   PubMed Web of Science ®Google Scholar
• Fujita N, Sugimoto R, Ma N, et al. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J Viral Hepat. 2008;15(7):498–507. doi:10.1111/j.1365-2893.2008.00972.x
   Web of Science ®Google Scholar
• Bolukbas C, Bolukbas FF, Horoz M, Aslan M, Celik H, Erel O. Increased oxidative stress associated with the severity of the liver disease in various forms of hepatitis B virus infection. BMC Infect Dis. 2005;5:95. doi:10.1186/1471-2334-5-95
   PubMed Web of Science ®Google Scholar
• Ivanov AV, Valuev-Elliston VT, Tyurina DA, et al. Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis. Oncotarget. 2017;8(3):3895–3932. doi:10.18632/oncotarget.13904
   PubMedGoogle Scholar
• Lee HR, Cho YY, Lee GY, You DG, Yoo YD, Kim YJ. A direct role for hepatitis B virus X protein in inducing mitochondrial membrane permeabilization. J Viral Hepat. 2018;25(4):412–420. doi:10.1111/jvh.12831
   Web of Science ®Google Scholar
• Lee YI, Hwang JM, Im JH, et al. Human hepatitis B virus-X protein alters mitochondrial function and physiology in human liver cells. J Biol Chem. 2004;279(15):15460–15471. doi:10.1074/jbc.M309280200
   PubMed Web of Science ®Google Scholar
• Xie H, Xie D, Zhang J, et al. ROS/NF-kappaB signaling pathway-mediated transcriptional activation of TRIM37 promotes HBV-associated hepatic fibrosis. Mol Ther Nucleic Acids. 2020;22:114–123. doi:10.1016/j.omtn.2020.08.014
   PubMedGoogle Scholar
• Yuan K, Lei Y, Chen HN, et al. HBV-induced ROS accumulation promotes hepatocarcinogenesis through Snail-mediated epigenetic silencing of SOCS3. Cell Death Differ. 2016;23(4):616–627. doi:10.1038/cdd.2015.129
   PubMed Web of Science ®Google Scholar
• Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2007;47:89–116. doi:10.1146/annurev.pharmtox.46.120604.141046
   PubMed Web of Science ®Google Scholar
• Zhang HT, Chen GG, Hu BG, et al. Hepatitis B virus x protein induces autophagy via activating death-associated protein kinase. J Viral Hepat. 2014;21(9):642–649. doi:10.1111/jvh.12191
   PubMed Web of Science ®Google Scholar
• Wang X, Lin Y, Liu S, et al. O-GlcNAcylation modulates HBV replication through regulating cellular autophagy at multiple levels. FASEB J. 2020;34(11):14473–14489. doi:10.1096/fj.202001168RR
   PubMed Web of Science ®Google Scholar
• He Q, Song X, Huang Y, et al. Dexamethasone stimulates Hepatitis B Virus (HBV) replication through autophagy. Med Sci Monit. 2018;24:4617–4624. doi:10.12659/MSM.906250
   PubMed Web of Science ®Google Scholar
• Xie M, Yang Z, Liu Y, Zheng M. The role of HBV-induced autophagy in HBV replication and HBV related-HCC. Life Sci. 2018;205:107–112. doi:10.1016/j.lfs.2018.04.051
   PubMed Web of Science ®Google Scholar
• Li J, Liu Y, Wang Z, et al. Subversion of cellular autophagy machinery by hepatitis B virus for viral envelopment. J Virol. 2011;85(13):6319–6333. doi:10.1128/JVI.02627-10
   PubMed Web of Science ®Google Scholar
• Sir D, Tian Y, Chen WL, Ann DK, Yen TS, Ou JH. The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication. Proc Natl Acad Sci U S A. 2010;107(9):4383–4388. doi:10.1073/pnas.0911373107
   PubMed Web of Science ®Google Scholar
• Lin Y, Wu C, Wang X, et al. Hepatitis B virus is degraded by autophagosome-lysosome fusion mediated by Rab7 and related components. Protein Cell. 2019;10(1):60–66. doi:10.1007/s13238-018-0555-2
   PubMed Web of Science ®Google Scholar
• Lin Y, Wu C, Wang X, et al. Synaptosomal-associated protein 29 is required for the autophagic degradation of hepatitis B virus. FASEB J. 2019;33(5):6023–6034. doi:10.1096/fj.201801995RR
   PubMed Web of Science ®Google Scholar
• Rautou PE, Mansouri A, Lebrec D, Durand F, Valla D, Moreau R. Autophagy in liver diseases. J Hepatol. 2010;53(6):1123–1134. doi:10.1016/j.jhep.2010.07.006
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang Y, Zhu X, et al. DEAD box protein 5 inhibits liver tumorigenesis by stimulating autophagy via interaction with p62/SQSTM1. Hepatology. 2019;69(3):1046–1063. doi:10.1002/hep.30300
   PubMed Web of Science ®Google Scholar
• Lan SH, Wu SY, Zuchini R, et al. Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of microRNA-224. Hepatology. 2014;59(2):505–517. doi:10.1002/hep.26659
   PubMed Web of Science ®Google Scholar
• Wu SY, Lan SH, Liu HS. Degradative autophagy selectively regulates CCND1 (cyclin D1) and MIR224, two oncogenic factors involved in hepatocellular carcinoma tumorigenesis. Autophagy. 2019;15(4):729–730. doi:10.1080/15548627.2019.1569918
   PubMed Web of Science ®Google Scholar
• Yan Y, Liu N, Lu L, et al. Autophagy enhances antitumor immune responses induced by irradiated hepatocellular carcinoma cells engineered to express hepatitis B virus X protein. Oncol Rep. 2013;30(2):993–999. doi:10.3892/or.2013.2531
   Web of Science ®Google Scholar
• Chen YY, Wang WH, Che L, et al. BNIP3L-dependent mitophagy promotes HBx-induced cancer stemness of hepatocellular carcinoma cells via glycolysis metabolism reprogramming. Cancers (Basel). 2020;12(3).
   Web of Science ®Google Scholar
• Wang MD, Wu H, Huang S, et al. HBx regulates fatty acid oxidation to promote hepatocellular carcinoma survival during metabolic stress. Oncotarget. 2016;7(6):6711–6726. doi:10.18632/oncotarget.6817
   PubMedGoogle Scholar
• Chen SL, Zhang CZ, Liu LL, et al. A GYS2/p53 negative feedback loop restricts tumor growth in HBV-related hepatocellular carcinoma. Cancer Res. 2019;79(3):534–545. doi:10.1158/0008-5472.CAN-18-2357
   PubMed Web of Science ®Google Scholar
• Chen W, Jiang J, Gong L, et al. Hepatitis B virus P protein initiates glycolytic bypass in HBV-related hepatocellular carcinoma via a FOXO3/miRNA-30b-5p/MINPP1 axis. J Exp Clin Cancer Res. 2021;40(1):1. doi:10.1186/s13046-020-01803-8
   Web of Science ®Google Scholar
• Zhou L, He R, Fang P, et al. Hepatitis B virus rigs the cellular metabolome to avoid innate immune recognition. Nat Commun. 2021;12(1):98. doi:10.1038/s41467-020-20316-8
   PubMed Web of Science ®Google Scholar
• Fisicaro P, Boni C, Barili V, Laccabue D, Ferrari C. Strategies to overcome HBV-specific T cell exhaustion: checkpoint inhibitors and metabolic re-programming. Curr Opin Virol. 2018;30:1–8. doi:10.1016/j.coviro.2018.01.003
   Web of Science ®Google Scholar
• Kapil S, Duseja A, Sharma BK, et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016;31(1):213–221. doi:10.1111/jgh.13058
   Web of Science ®Google Scholar
• Zeng Y, Chen S, Fu Y, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. J Viral Hepat. 2020;27(2):143–155. doi:10.1111/jvh.13216
   Web of Science ®Google Scholar
• Liu Q, Li F, Zhuang Y, et al. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma. Gut Pathog. 2019;11:1. doi:10.1186/s13099-018-0281-6
   PubMed Web of Science ®Google Scholar
• Toffanin S, Cornella H, Harrington A, Llovet JM. HCC is promoted by bacterial translocation and TLR-4 signaling: a new paradigm for chemoprevention and management. Hepatology. 2012;56(5):1998–2000. doi:10.1002/hep.26080
   Google Scholar
• Zheng B, Yang Y, Han Q, Yin C, Pan Z, Zhang J. STAT3 directly regulates NKp46 transcription in NK cells of HBeAg-negative CHB patients. J Leukoc Biol. 2019;106(4):987–996. doi:10.1002/JLB.2A1118-421R
   Web of Science ®Google Scholar
• Sun C, Sun H, Zhang C, Tian Z. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol. 2015;12(3):292–302. doi:10.1038/cmi.2014.91
   Web of Science ®Google Scholar
• Xu D, Han Q, Hou Z, Zhang C, Zhang J. miR-146a negatively regulates NK cell functions via STAT1 signaling. Cell Mol Immunol. 2017;14(8):712–720. doi:10.1038/cmi.2015.113
   PubMed Web of Science ®Google Scholar
• Yu X, Lan P, Hou X, et al. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1beta production via suppressing the NF-kappaB pathway and ROS production. J Hepatol. 2017;66(4):693–702. doi:10.1016/j.jhep.2016.12.018
   PubMed Web of Science ®Google Scholar
• Faure-Dupuy S, Delphin M, Aillot L, et al. Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection. J Hepatol. 2019;71(6):1086–1098. doi:10.1016/j.jhep.2019.06.032
   Web of Science ®Google Scholar
• Raziorrouh B, Schraut W, Gerlach T, et al. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology. 2010;52(6):1934–1947. doi:10.1002/hep.23936
   PubMed Web of Science ®Google Scholar
• Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol. 2011;54(2):209–218. doi:10.1016/j.jhep.2010.07.009
   PubMed Web of Science ®Google Scholar
• Fisicaro P, Barili V, Montanini B, et al. Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat Med. 2017;23(3):327–336. doi:10.1038/nm.4275
   PubMed Web of Science ®Google Scholar
• Zong L, Peng H, Sun C, et al. Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice. Nat Commun. 2019;10(1):221. doi:10.1038/s41467-018-08096-8
   Web of Science ®Google Scholar
• Liu X, He L, Han J, et al. Association of neutrophil-lymphocyte ratio and T lymphocytes with the pathogenesis and progression of HBV-associated primary liver cancer. PLoS One. 2017;12(2):e0170605. doi:10.1371/journal.pone.0170605
   PubMed Web of Science ®Google Scholar
• Tajiri K, Baba H, Kawai K, et al. Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection. J Gastroenterol Hepatol. 2016;31(7):1291–1299. doi:10.1111/jgh.13287
   PubMed Web of Science ®Google Scholar
• Yang P, Li QJ, Feng Y, et al. TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22(3):291–303. doi:10.1016/j.ccr.2012.07.023
   PubMed Web of Science ®Google Scholar
• Li K, Liu H, Guo T. Th17/Treg imbalance is an indicator of liver cirrhosis process and a risk factor for HCC occurrence in HBV patients. Clin Res Hepatol Gastroenterol. 2017;41(4):399–407. doi:10.1016/j.clinre.2016.12.004
   Web of Science ®Google Scholar
• Liu X, Li M, Wang X, et al. PD-1(+) TIGIT(+) CD8(+) T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68(12):2041–2054. doi:10.1007/s00262-019-02426-5
   PubMed Web of Science ®Google Scholar
• Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019;68(5):916–927. doi:10.1136/gutjnl-2018-316510
   PubMed Web of Science ®Google Scholar
• Li S, Li S, Wu S, Chen L. Exosomes modulate the viral replication and host immune responses in HBV infection. Biomed Res Int. 2019;2019:2103943.
   Web of Science ®Google Scholar
• Kakizaki M, Yamamoto Y, Yabuta S, Kurosaki N, Kagawa T, Kotani A. The immunological function of extracellular vesicles in hepatitis B virus-infected hepatocytes. PLoS One. 2018;13(12):e0205886. doi:10.1371/journal.pone.0205886
   Web of Science ®Google Scholar
• Kapoor NR, Chadha R, Kumar S, Choedon T, Reddy VS, Kumar V. The HBx gene of hepatitis B virus can influence hepatic microenvironment via exosomes by transferring its mRNA and protein. Virus Res. 2017;240:166–174. doi:10.1016/j.virusres.2017.08.009
   PubMed Web of Science ®Google Scholar
• Yang Y, Han Q, Hou Z, Zhang C, Tian Z, Zhang J. Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. Cell Mol Immunol. 2017;14(5):465–475. doi:10.1038/cmi.2016.24
   PubMed Web of Science ®Google Scholar
• Shi Y, Du L, Lv D, et al. Exosomal interferon-induced transmembrane protein 2 transmitted to dendritic cells inhibits interferon alpha pathway activation and blocks anti-Hepatitis B virus efficacy of exogenous interferon alpha. Hepatology. 2019;69(6):2396–2413. doi:10.1002/hep.30548
   Web of Science ®Google Scholar
• Liu DX, Li PP, Guo JP, et al. Exosomes derived from HBV-associated liver cancer promote chemoresistance by upregulating chaperone-mediated autophagy. Oncol Lett. 2019;17(1):323–331. doi:10.3892/ol.2018.9584
   Web of Science ®Google Scholar
• Petersen J, Thompson AJ, Levrero M. Aiming for cure in HBV and HDV infection. J Hepatol. 2016;65(4):835–848. doi:10.1016/j.jhep.2016.05.043
   Web of Science ®Google Scholar
• Han Q, Hou Z, Yin C, Zhang C, Zhang J. 5ʹ-triphosphate siRNA targeting HBx elicits a potent anti-HBV immune response in pAAV-HBV transfected mice. Antiviral Res. 2019;161:36–45. doi:10.1016/j.antiviral.2018.11.006
   Web of Science ®Google Scholar
• Yao Z, Qiao Y, Li X, et al. Exosomes exploit the virus entry machinery and pathway to transmit alpha interferon-induced antiviral activity. J Virol. 2018;92(24). doi:10.1128/JVI.01578-18.
   Web of Science ®Google Scholar
• Li J, Liu K, Liu Y, et al. Exosomes mediate the cell-to-cell transmission of IFN-alpha-induced antiviral activity. Nat Immunol. 2013;14(8):793–803. doi:10.1038/ni.2647
   PubMed Web of Science ®Google Scholar
• Jesus S, Soares E, Cruz MT, Borges O. Exosomes as adjuvants for the recombinant hepatitis B antigen: first report. Eur J Pharm Biopharm. 2018;133:1–11. doi:10.1016/j.ejpb.2018.09.029
   PubMed Web of Science ®Google Scholar
• Horng JH, Lin WH, Wu CR, et al. HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice. J Biomed Sci. 2020;27(1):70. doi:10.1186/s12929-020-00662-x
   PubMed Web of Science ®Google Scholar
• Zhao HJ, Han QJ, Wang G, et al. Poly I:C-based rHBVvac therapeutic vaccine eliminates HBV via generation of HBV-specific CD8(+) effector memory T cells. Gut. 2019;68(11):2032–2043. doi:10.1136/gutjnl-2017-315588
   PubMed Web of Science ®Google Scholar
• Wang W, Zhou X, Bian Y, et al. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nat Nanotechnol. 2020;15(5):406–416. doi:10.1038/s41565-020-0648-y
   PubMed Web of Science ®Google Scholar